The biotherapeutic industry continues to develop more complex and effective molecules for patients which in turn requires the quality control and characterization laboratories to modernise their analytical approaches to ensure product quality. These laboratories use a vast array of instrumentation and techniques to monitor the CQAs of their products. The use of mass spectrometry in the pharmaceutical industry is increasingly on the rise due to improvements in software functionality, data integrity control and ease of use of MS instruments. The MAM and iMAM workflows are powerful analytical approaches that can be used to combine and reduce existing conventional analytical assays. Mass spectrometry has the potential to generate more accurate and detailed information about biotherapeutic CQAs during both the discovery phase of molecules lifecycle and the quality control analysis phase .